Monitor for divesiran Phase 2 topline results in 3Q 2026, which will be a key catalyst for the stock. The updated presentation provides no new financial data or guidance, so near-term trading impact is limited.
Price Chart
Executive Summary
Silence Therapeutics filed an updated corporate presentation on June 23, 2026, highlighting pipeline progress across its siRNA programs. Key milestones include expected topline Phase 2 results for divesiran in polycythemia vera in 3Q 2026, Phase 1 data for SLN312 in dyslipidemia, and preclinical updates for SLN365 (GPR146) and SLN098 (INHBE). No financial data or guidance was provided.
Key Facts
- Filed updated corporate presentation under Item 7.01 Regulation FD Disclosure
- SANRECO Phase 2 study for divesiran (TMPRSS6) in polycythemia vera fully enrolled; topline results expected in 3Q 2026
- SLN312 (ANGPTL3) Phase 1 data presented at 2026 EAS Congress showing robust ANGPTL3 reductions; Silence to re-gain exclusive rights post-Phase 1
- SLN365 (GPR146) demonstrated >80% mRNA knockdown in NHP; potential IND filing in 2H 2027
- SLN098 (INHBE) showed ~90% protein knockdown sustained for at least 3 months in NHP; potential IND filing by year-end 2027
- Zerlasiran (LPA) described as Phase 3 ready; positioned for potential third-party partnership
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- Clinical trial risks for divesiran Phase 2 and other pipeline programs
- Regulatory and competitive risks in siRNA therapeutics
- Dependence on partnership for zerlasiran advancement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-279577 |
| Document: sln-ex99_1.htm | 0001193125-26-279577 |
| Document: 0001193125-26-279577-index-headers.html | 0001193125-26-279577 |
| Document: 0001193125-26-279577-index.html | 0001193125-26-279577 |
| Document: 0001193125-26-279577.txt | 0001193125-26-279577 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 424B5 | $14.72 $13.55 | ▲ +7.95% | ▲ +6.89% | $10.55 (+28.33%) |
Aug 10, 2026 7w ago | 8-K | $15.43 $13.69 | ▼ −11.28% | ▼ −10.36% | $10.55 (−31.63%) |
Aug 10, 2026 7w ago | 8-K | $15.43 $13.69 | ▼ −11.28% | ▼ −10.36% | $10.55 (−31.63%) |
Jun 23, 2026 14w ago | 8-K | $9.16 $11.83 | ▲ +29.15% | ▲ +27.22% | $10.55 (+15.17%) |
Mar 5, 2026 30w ago | 8-K | $5.50 $5.94 | ▲ +8.00% | ▲ +11.79% | $10.55 (+91.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access